10 results about "Depigmentation" patented technology

Vitiligo is a complex auto-immune skin disease resulting in melanocytes loss and skin depigmentation. Following-up on their previous work identifying mitochondrial DNA (mtDNA) in skin biopsies from some vitiligo patients, the inventors demonstrate here that melanocytes from non-lesional skin present elevated numbers of mtDNA variants associated with mtDNA release and can be classified as function of their number of mtDNA variants in low-variant (LV) and high-variant (HV) load. Vitiligo HV melanocytes display increased ROS production, reduced antioxidant capacity, elevated mitochondrial function and mtDNA release as compared to Vitiligo LV and healthy melanocytes. Sensing of mtDNA by the cGAS-STING pathway results in pro-inflammatory cytokine and chemokines production promoting the recruitment of cytotoxic CD8+ T cells. This cascade of events can be blocked with TBK1 inhibitors suggesting new therapeutic approaches for sub-population of vitiligo patients displaying HV mtDNA phenotype. The present invention relates to method for the treatment of vitiligo in a subject in need thereof comprising a step of administrating to the subject a therapeutically effective amount of TANK-binding kinase 1 (TBK1) inhibitor.

The present invention relates to a composition comprising cysteamine, azabenzene-4-carboxamide and glycolic acid. The present invention also relates to the cosmetic use thereof for inhibiting, reducing or preventing skin pigmentation and to the therapeutical use thereof for inhibiting, reducing or preventing skin hyperpigmentation diseases or disorders.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of XBD-173 or its pharmaceutically acceptable salts in the preparation of remedies for treating and / or preventing depigmentation diseases caused by pigment synthesis disorders, particularly in the preparation of remedies for treating and / or preventing vitiligo, leukoderma, pityriasis alba, and albinism. Experiments have shown that XBD-173 can significantly increase melanin synthesis and promote repigmentation in the dorsal lesions of vitiligo mice, while exhibiting no significant toxicity. In summary, XBD-173 has a clear mechanism of action, significant effects, and no significant side effects, demonstrating significant advantages and advancements compared to existing drugs.

The treatment according to the invention involves the use of at least one peptide of general formula X-(Xaa)nGQPR(Xaa)mZ for a non-therapeutic cosmetic hair treatment.In the formula, Xaa is an amino acid chosen from proline (P, Pro), glycine (G, Gly), alanine (A, Ala), valine (V, Val), leucine (L, Leu) and isoleucine (I, Ile), the Xaa being chosen independently of each other; with n and m integers which may be equal or different between 0 and 5; at the N-terminal end X is chosen from H, CO-R1, or SO2-R1; at the C-terminal end Z is chosen from OH, OR1, NH2, NHR1, or NR1R2; R1 and R2 being, independently of each other, chosen from an alkyl, aryl, aralkyl, alkylaryl, alkoxy, saccharide and aryloxy group, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonyl, phosphorylated and / or sulfur-containing, said group having from 1 to 24 carbon atoms and having in its skeleton one or more O, S and / or N heteroatoms. The preferred peptide sequences are Pal-GQPR-OH or Pal-GQPR-NH2.These peptides act on multiple levels: hair follicle stem cells, dermal papillae, signaling pathways, and the extracellular matrix. They can be used for cosmetic hair treatments, particularly to protect the structure of hair and / or body hair, including eyelashes and eyebrows, slow hair loss, induce and / or stimulate growth, prevent depigmentation, and / or induce pigmentation.

The present invention relates to a nutritional and health care composition for oral administration, comprising an extract of Glycyrrhiza glabra L. and an extract of Olea eupaea L.. The nutritional and health care composition is characterized in that the nutritional and health care composition comprises an extract of Glycyrrhiza glabra L. and an extract of Olea eupaea L.. The formulations are suitable for use as skin decolorizing and bleaching agents and for controlling skin protein saccharification.

The present invention discloses an oil gel bead essence, which comprises an oil gel bead mixture, a traditional Chinese medicine extraction composition, a skin conditioner composition, an additive composition and water, the oil gel bead mixture comprises one or more humectants, the humectants comprise C16-C24 saturated fatty alcohol, the oil gel bead comprises liquid grease, and the liquid grease comprises one or more essence components. The traditional Chinese medicine extract composition comprises a honeysuckle extract, an aloe extract, a purple chrysanthemum extract, a fructus cnidii extract and a coptis chinensis extract, and the skin conditioner composition comprises a Kava pepper root extract, a crithmum maritimum extract, tocopherol and deer bone collagen. The additive composition comprises a thickening agent, an aromatic agent, a thickening agent, an antioxidant and a freckle removing agent, and is prepared from the following components in parts by weight: 20 to 30 parts of oil gel bead mixture, 5 to 10 parts of traditional Chinese medicine extract composition, 3 to 5 parts of skin conditioner composition, 1 to 2 parts of additive composition and 10 to 15 parts of water. The traditional Chinese medicine composition can effectively relieve inflammation, remove acnes and moisten skin, and is lasting in moisture retention and drug effect.

The present invention relates to a whitening composition comprising a whitening effective amount of a compound of formula (I), or a tautomer, stereoisomer, hydrate, solvate, salt, or polymorph thereof, wherein R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、m and n are as defined in the specification and claims. The present invention also relates to a compound of formula (I2) or a tautomer, stereoisomer, hydrate, solvate, salt, or polymorph thereof, wherein R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、and R 7 are as defined in the specification and claims. The present invention also relates to the use of at least one compound of formula (I) or any subgroup thereof, or a mixture thereof, as a depigmenting agent. The present invention also relates to the use of at least one compound of formula (I) or any subgroup thereof, or the use of a whitening composition, for preventing and / or reducing pigmentation of normal skin. The present invention also relates to the use of at least one compound, or the use of a whitening composition according to the first aspect, for reducing the amount of melanin in melanocytes, for reducing melanin synthesis, for impairing melanin transport, and / or for impairing the distribution of melanin in the upper basal layer. JPEG2026520910000038.jpg3191

The invention provides application of apocynin in preparation of a medicine for preventing and / or treating depigmentation skin diseases, and belongs to the technical field of skin disease medicine manufacturing. The invention discloses application of apocynin or an apocynin derivative in preparation of a medicine for preventing and / or treating depigmentation skin diseases, especially vitiligo. The medicine prepared from the apocynin can effectively recover leucoderma model mouse skin pigments, effectively reduce expression of model mouse skin inflammatory factors and reduce infiltration of CD8 + T cells. Therefore, the apocynin or the apocynin derivative achieves the purpose of treating depigmentation skin diseases by relieving skin inflammation, protecting melanocytes from being oxidized and damaged and promoting melanogenesis. The invention not only expands the medical application of apocynin, but also provides a new way for clinical treatment of depigmentation dermatosis.

Vitiligo is a complex auto-immune skin disease resulting in melanocytes loss and skin depigmentation. Following-up on their previous work identifying mitochondrial DNA (mtDNA) in skin biopsies from some vitiligo patients, the inventors demonstrate here that melanocytes from non-lesional skin present elevated numbers of mtDNA variants associated with mtDNA release and can be classified as function of their number of mtDNA variants in low-variant (LV) and high-variant (HV) load. Vitiligo HV melanocytes display increased ROS production, reduced antioxidant capacity, elevated mitochondrial function and mtDNA release as compared to Vitiligo LV and healthy melanocytes. Sensing of mtDNA by the cGAS-STING pathway results in pro-inflammatory cytokine and chemokines production promoting the recruitment of cytotoxic CD8+ T cells. This cascade of events can be blocked with NRF2 activators suggesting new therapeutic approaches for sub-population of vitiligo patients displaying HV mtDNA phenotype. The present invention relates to method for the treatment of vitiligo in a subject in need thereof comprising a step of administrating to the subject a therapeutically effective amount of Nuclear factor erythroid 2 -related factor 2 (NRF2) activator.